Randomized Trial of Cisplatin and Carboplatin versus Cisplatin, Vinblastine and Bleomycin in Ovarian Cancer
| Autor: | Fumitaka Kikkawa, Shigehiko Mizutani, Katsuji Matsuzawa, Michiyasu Kawai, Yoshitaro Arii, Iwao Kobayashi, Nobuo Nakashima |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
medicine.medical_specialty Ovariectomy medicine.medical_treatment Urology Antineoplastic Agents Vinblastine Disease-Free Survival Carboplatin Bleomycin chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Aged Proportional Hazards Models Ovarian Neoplasms Cisplatin Chemotherapy business.industry Carcinoma Obstetrics and Gynecology PVB Regimen Middle Aged Prognosis medicine.disease Surgery Survival Rate Regimen Reproductive Medicine chemistry Chemotherapy Adjuvant Multivariate Analysis Female Ovarian cancer business medicine.drug |
| Zdroj: | Gynecologic and Obstetric Investigation. 50:269-274 |
| ISSN: | 1423-002X 0378-7346 |
| Popis: | Between January 1992 and July 1997, 202 cases of epithelial ovarian cancer were registered and assigned randomly to a combination of cisplatin and carboplatin (PP group), or cisplatin, vinblastine and bleomycin (PVB group). We analyzed 189 patients whose clinical records were available. The PP chemotherapeutic regimen was advantageous in terms of overall survival compared to the PVB regimen until 4 years after the initial operation. However, the 5-year survival rates were almost the same in both groups. However, in stage III patients, the mean survival time in the PP group was 51.4 months and that in the PVB group was 23.3 months, and there was a statistically significant difference in the survival curves between the two groups (p = 0.0158). The 5-year survival rates were 31.1 and 20.4% in the PP and PVB groups, respectively, in stage III patients. The PP regimen was also significantly superior in patients with macroscopic residual tumor after the initial operation, and the 5-year survival rates were 25.7 and 10.1% in the PP and PVB groups, respectively (p = 0.0128). However, there was no significant difference between the two regimens in patients without macroscopic residual tumor. Cox’s proportional hazards regression analysis showed that tumor stage, presence of macroscopic residual tumor, and the chemotherapeutic regimen used were significant prognostic factors. In conclusion, the PP chemotherapeutic regimen is superior to the PVB regimen especially in the treatment of advanced ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|